This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
The Joint Corp. (JYNT) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
The Joint Corp. (JYNT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
The Joint Corp. (JYNT) Moves 10.1% Higher: Will This Strength Last?
by Zacks Equity Research
The Joint Corp. (JYNT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
The Joint (JYNT) Rises 30% as Q4 Earnings Beat on Higher Clinics
by Zacks Equity Research
The Joint (JYNT) expects 2024 system-wide sales to be within $530-$545 million.
The Joint Corp. (JYNT) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
The Joint Corp. (JYNT) delivered earnings and revenue surprises of 133.33% and 3.34%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
The Joint (JYNT) to Report Q4 Earnings: Here Are the Key Drivers
by Zacks Equity Research
The Joint's (JYNT) fourth-quarter 2023 results are likely to reflect higher expenses and patient volumes.
Select Medical (SEM) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Select Medical (SEM) delivered earnings and revenue surprises of 16.13% and 3.02%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Is Cigna (CI) Nearing a Medicare Advantage Divestment Deal?
by Zacks Equity Research
Cigna's (CI) Medicare Advantage unit's divestment is expected to fetch around $3-$4 billion.
Cigna (CI) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Cigna (CI) delivered earnings and revenue surprises of 1.65% and 2.32%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
The Joint (JYNT) Forays Into West Virginia Chiropractic Market
by Zacks Equity Research
The Joint's (JYNT) new facility is positioned near the West Virginia University campus, at a high-traffic shopping center.
The Joint (JYNT) Q2 Earnings Miss Estimates, 2023 View Down
by Zacks Equity Research
The Joint (JYNT) expects to open 100-120 franchised clinics in 2023 compared with 121 opened last year.
The Joint Corp. (JYNT) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
The Joint Corp. (JYNT) delivered earnings and revenue surprises of -133.33% and 1.80%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
The Joint (JYNT) Reaches 900th Clinic Mark With New Texas Unit
by Zacks Equity Research
The Joint (JYNT) moves from the 800th to the 900th clinic milestone in less than a year.
Humana (HUM) Surpasses Q2 Earnings Estimates
by Zacks Equity Research
Humana (HUM) delivered earnings and revenue surprises of 0.68% and 0.34%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Molina (MOH) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Molina (MOH) delivered earnings and revenue surprises of 11.88% and 0.52%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Here's Why Hold Strategy is Apt for The Joint (JYNT) Stock Now
by Zacks Equity Research
The Joint (JYNT) is expected to keep growing due to rising patient visits and new clinic openings.
The Joint (JYNT) Buys Wisconsin Regional Developer Zone Rights
by Zacks Equity Research
The Joint (JYNT) expects the Wisconsin region to hold a total of 53 clinics, of which 21 are currently operating.
The Joint Corp. (JYNT) Surges 10.0%: Is This an Indication of Further Gains?
by Zacks Equity Research
The Joint Corp. (JYNT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
The Joint Corp. (JYNT) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
The Joint Corp. (JYNT) delivered earnings and revenue surprises of 850% and 3.60%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Humana (HUM) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Humana (HUM) delivered earnings and revenue surprises of 1.41% and 1.61%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
The Joint (JYNT) to Enter Puerto Rico With New Franchise Deal
by Zacks Equity Research
The Puerto Rico deal with the Comerfords marks The Joint's (JYNT) first franchise deal outside the continental United States.
The Joint Corp. (JYNT) Misses Q4 Earnings Estimates
by Zacks Equity Research
The Joint Corp. (JYNT) delivered earnings and revenue surprises of -42.86% and 1.36%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Molina (MOH) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Molina (MOH) delivered earnings and revenue surprises of 0.99% and 4.57%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Centene (CNC) Q4 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Centene (CNC) delivered earnings and revenue surprises of -1.15% and 0.08%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
The Joint (JYNT) 2022 Visits Grow to 12.2M, Adds New Clinics
by Zacks Equity Research
The Joint's (JYNT) clinic network grows 19% year over year in 2022.
The Joint (JYNT) Expands Operations to Alaska With 3 Clinics
by Zacks Equity Research
The Joint's (JYNT) expansionary move is expected to be a prudent one, given the growing demand for affordable and convenient chiropractic care in the region.